Jubilant Foodworks' (JUBI's) Q4FY16 results disappointed at the revenue, EBITDA and PAT levels. While revenues were 4.2% below expectations, EBITDA margins contracted by 80bps y-o-y, with adjusted PAT declining 6.6% y-o-y.
Q4FY16 was a mixed quarter for the Indian pharma sector. While revenue growth accelerated, margins moderated despite one-off gains. The key headwinds were 1) rising R&D, 2) pricing pressure and 3) USFDA actions.
We believe it is extremely desirable that the bank contours the stress and provides forward guidance. This provides a reasonable upper bound to stress levels, as current stress assumptions for the street...
“Certain bright spots in the industrial horizon included some movement in stalled projects, traction in the renewable energy market, make in India policy initiatives, and the investment to revamp and upgrade the railways by
We recently interacted with the management of Gujarat Pipavav Port (Pipavav) on business operations. Focused efforts to win new clients have seen it winning another new liner recently post the incremental two liners in 3QFY16